key: cord-0312387-qe7f3skx authors: Vagima, Yaron; Gur, David; Aftalion, Moshe; Moses, Sarit; Levy, Yinon; Makovitzki, Arik; Holtzman, Tzvi; Oren, Ziv; Segula, Yaniv; Fatelevich, Ella; Tidhar, Avital; Zauberman, Ayelet; Rotem, Shahar; Mamroud, Emanuelle; Steinberger-Levy, Ida title: Phage therapy potentiates second-line antibiotic treatment against pneumonic plague date: 2022-02-07 journal: bioRxiv DOI: 10.1101/2022.02.07.479346 sha: eac53e9eecf8f1cdf9fd34027539cb8d88695dbe doc_id: 312387 cord_uid: qe7f3skx Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by Yersinia pestis bacteria, can currently be treated efficiently with antibiotics. However, in the case of multidrug-resistant (MDR) bacteria, alternative treatments are required. Bacteriophage (phage) therapy has shown efficient antibacterial activity in various experimental animal models and in human patients infected with different MDR pathogens. Herein, we evaluated the efficiency of ϕA1122 and PST phage therapy, alone or in combination with second-line antibiotics, using a well-established mouse model of pneumonic plague. Phage treatment significantly delayed mortality and limited bacterial proliferation in the lungs. However, the treatment did not prevent bacteremia, suggesting that phage efficiency may decrease in circulation. Indeed, in vitro phage proliferation assays indicated that blood has inhibitory effects on lytic activity, which may be the major cause of treatment inefficiency. Combining phage therapy and second-line ceftriaxone treatment, which are individually insufficient, provided protection that led to survival of all infected animals, presenting a synergistic protective effect that represents a proof of concept for efficient combinatorial therapy in an emergency event of a plague outbreak involving MDR Y. pestis strains. Author summary Plague, caused by Yersinia pestis bacteria, can be efficiently treated with antibiotics. However, alternative therapies for the case of natively evolved or maliciously generated antibiotic-resistant Y. pestis must be developed. Due to the global increase in antibiotic resistance, there is renewed interest in examining the effectiveness of bacteriophage-based alternative therapies. Here, using a mouse model of pneumonic plague, we demonstrate that phage treatment significantly delayed mortality. By monitoring bioluminescence of engineered Y. pestis strain and live bacterial counts, we show that phage therapy effectively inhibited bacterial proliferation in the lung but not in blood. In vitro analyses showed decreased phage activity in the presence of blood, which probably explains the low efficacy of phage treatment alone. Because combination therapies will be used in an emergency situation, we tested the efficacy of Y. pestis-lysing phages as adjunctive therapy with a second-line antibiotic, ceftriaxone. Whereas each individual treatment was insufficient, the combination provided effective protection and rescued all infected animals. These results clearly demonstrated the synergistic effect of combined phage and antibiotic therapy and represent a proof of concept for this alternative therapy against multidrug-resistant Y. pestis strains. Author summary 22 Plague, caused by Yersinia pestis bacteria, can be efficiently treated with antibiotics. 23 However, alternative therapies for the case of natively evolved or maliciously generated 24 antibiotic-resistant Y. pestis must be developed. Due to the global increase in antibiotic 25 resistance, there is renewed interest in examining the effectiveness of bacteriophage-26 based alternative therapies. Here, using a mouse model of pneumonic plague, we 27 demonstrate that phage treatment significantly delayed mortality. By monitoring 28 bioluminescence of engineered Y. pestis strain and live bacterial counts, we show that 29 phage therapy effectively inhibited bacterial proliferation in the lung but not in blood. In 30 vitro analyses showed decreased phage activity in the presence of blood, which probably 31 explains the low efficacy of phage treatment alone. Because combination therapies will 32 be used in an emergency situation, we tested the efficacy of Y. pestis-lysing phages as 33 adjunctive therapy with a second-line antibiotic, ceftriaxone. 34 Whereas each individual treatment was insufficient, the combination provided effective 35 protection and rescued all infected animals. These results clearly demonstrated the 36 synergistic effect of combined phage and antibiotic therapy and represent a proof of 37 concept for this alternative therapy against multidrug-resistant Y. pestis strains. Yersinia pestis, a gram-negative bacterium and the etiological agent of plague, is a lethal 44 pathogen that has led to three world pandemics throughout human history [1, 2] . 45 Although natural plague outbreaks are rare, plague is considered a reemerging disease 46 [3, 4] . A recent large outbreak occurred in Madagascar in 2017, where many patients 47 presented with the pneumonic form of the disease [5, 6] . Due to its lethality and the 48 potential for person-to-person infectivity, Y. pestis is classified by the Centers for Disease 49 Control and Prevention (CDC) as a tier-1 select agent [1, 7] . Natural exposure of humans 50 to the bacteria may occur through a carrier flea bite, leading to bubonic or septic plague 51 that can be further developed into a secondary pneumonic plague, or by air transmission, 52 leading to primary pneumonic plague [1] . Pneumonic plague is a rapidly deteriorating 53 disease that, if not immediately treated with the recommended antibiotic, leads to death Lytic phages are bacterial viruses that demonstrate high specificity toward their hosts. 63 Phage replication inside the host bacteria leads to bacterial lysis and cell death, releasing 64 progeny virions in the so-called "lytic cycle". The potential of using phages for 65 antimicrobial therapy has been known for more than a century, since phages were 66 independently identified by Frederik Twort (in 1915) phage concentration in the lung (~1x10 9 PFU/lungs, Fig 1B) . Moreover, high phage 101 concentrations were maintained in the lungs for at least 4 days ( Fig 1B) ). However, in the following days, bacteria also appeared in the circulation of phage-134 treated mice ( Fig 2E) . The appearance of Y. pestis in the blood negatively correlated with 135 the phage amount, which was low at 48 hpi and decreased further to under the limit of 136 detection at 96 hpi ( Fig 2F) . We therefore concluded that while Y. pestis growth in the 137 lungs of treated mice was restricted, the reduction in phage amount in the blood during 138 disease progression enabled Y. pestis dissemination/propagation in the circulation, which 139 finally led to mouse death (Fig 2A) . (100xLD 50 ) and treated with phage, ceftriaxone or a combination of both (Fig 7A) . For 240 phage treatment, we used a cocktail composed of both фA1122 and PST (1x10 9 PFU of 241 each per dose). Antibiotic treatment with ceftriaxone rescued only 20% of the mice (Fig 242 7B ), and as was found for treatment with PST or фA1122 alone (Fig 6) , treatment with the 243 phage cocktail delayed mortality; however, all mice succumbed to the infection (Fig 7B) . 244 In contrast, the phage-antibiotic combination treatment was highly effective, leading to 245 the survival of all infected animals ( Fig 7B) The experience of the current emerging COVID-19 pandemic with its broad effects on 264 humankind has highlighted the need for preparedness for bacterial-derived outbreaks. In 265 this regard, a major concern is the appearance of highly transmissible MDR pathogens for 266 which current antibiotics may become ineffective. In the case of the plague-causing Y. the blood that those in control nontreated counterparts (Fig 2) . However, although 300 disease progression was delayed, phage administration was unable to provide protection, 301 and all treated animals succumbed to the infection (Figs 2-3) . Delayed mortality seemed 302 to be associated with low phage concentrations in the circulation (Figs 1 and 5) lytic activity in the presence of mouse blood (Fig 4) phage, which retained in vitro activity in the presence of blood, still yielded a similarly low 309 therapeutic efficiency in vivo as фA1122 (Fig 6) , indicating that additional limiting factors Plague as a 465 biological weapon: Medical and public health management Antibiotic therapy of plague: A review Beating 473 the bio-terror threat with rapid antimicrobial susceptibility testing Epidemiological characteristics of an 478 urban plague epidemic in Madagascar The rise of pneumonic plague in Madagascar: Current plague outbreak 483 breaks usual seasonal mould Plague: From Natural Disease to Bioterrorism Transferable plasmid-mediated resistance to 489 streptomycin in a clinical isolate of Yersinia pestis Resistance of Yersinia pestis to 492 antimicrobial agents Multiple 496 antimicrobial resistance in plague: An emerging public health risk Transmission of Antimicrobial Resistant Yersinia pestis 501 During a Pneumonic Plague Outbreak Predictors of survival after 505 vaccination in a pneumonic plague model 508 14. d'Herelle, F. Bacteriophage as a Treatment in Acute Medical and Surgical 509 Infections Phage Therapy: A Renewed 511 Approach to Combat Antibiotic-Resistant Bacteria The safety and 515 toxicity of phage therapy: A review of animal and clinical studies Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and 520 Antibiotics Combination Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a 525 Disseminated Resistant Acinetobacter baumannii Infection Phage 528 Therapy for Multi-Drug Resistant Respiratory Tract Infections Inhalational gentamicin treatment is effective 532 against Pneumonic Plague In A Mouse Model Antibiotic treatment 536 of experimental pneumonic plague in mice Postexposure administration of a Yersinia pestis live vaccine for 540 potentiation of second-line antibiotic treatment against pneumonic plague de traitement de la peste bubonique par le bacteriophage Bacteriophage therapy of experimental 546 bubonic plague in mice Bacteriophage-resistant mutants in Yersinia 551 pestis: identification of phage receptors and attenuation for mice Bacteriophages of Yersinia pestis Advances i Laboratory Manual of Plague Diagnostic Tests Characterization of Yersinia pestis phage lytic activity in 560 human whole blood for the selection of efficient therapeutic phages Propagation of S. aureus Phage K in Presence of Human 564 Blood Metals Enhance the 566 Killing of Bacteria by Bacteriophage in Human Pharmacologically aware phage therapy: 569 pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in 570 animal and human bodies. Microbiol Can phage effectively treat 572 multidrug-resistant plague? Bacteriophage Fighting Pathogenic Bacteria on Two 575 Fronts: Phages and Antibiotics as Combined Strategy A combination therapy of Phages and Antibiotics: Two is better than one Computational design of 581 phage cocktails based on phage-bacteria infection networks In vitro antibiotic susceptibilities of Yersinia pestis determined by 585 broth microdilution following CLSI methods A rapid molecular test for determining Yersinia 33 589 pestis susceptibility to ciprofloxacin by the quantification of differentially 590 expressed marker genes Identification of the lipopolysaccharide core of Yersinia 594 pestis and Yersinia pseudotuberculosis as the receptor for bacteriophage φA1122 Shafferman, 597 A.; Mamroud, E. Circumventing Y. pestis Virulence by Early Recruitment of 598 Neutrophils to the Lungs during Pneumonic Plague Targeting of the Yersinia pestis F1 capsular antigen 602 by innate-like B1b cells mediates a rapid protective response against bubonic 603 plague 460 We would like to thank Professor Mikael Skurnik for kindly providing the фA1122 phage.